Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/118953
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Santín Cerezales, Miguel | - |
dc.contributor.author | Shaw Perujo, Evelyn | - |
dc.contributor.author | Garcia, Maria Jose | - |
dc.contributor.author | Delejido, Antonio | - |
dc.contributor.author | Rodríguez de Castro, Eduardo | - |
dc.contributor.author | Rota Roca, Rosa | - |
dc.contributor.author | Altés, Jordi | - |
dc.contributor.author | Baguena, Francisco | - |
dc.contributor.author | Valero, Silvia | - |
dc.contributor.author | Sala, Montserrat | - |
dc.contributor.author | Casanova Rituerto, Aurora | - |
dc.contributor.author | HCV/HIV-01 Study Team | - |
dc.date.accessioned | 2018-01-10T11:29:09Z | - |
dc.date.available | 2018-01-10T11:29:09Z | - |
dc.date.issued | 2006-04-19 | - |
dc.identifier.issn | 0889-2229 | - |
dc.identifier.uri | http://hdl.handle.net/2445/118953 | - |
dc.description.abstract | Low response rates and concerns about safety have limited the implementation of treatment for chronic hepatitis C (CHC) in patients with HIV infection. The efficacy and safety of pegylated interferon (peg-IFN) plus ribavirin in HIV-infected patients with CHC were evaluated in a prospective, open-label, multicenter study. Sixty patients with persistently high transaminases, positive HCV-RNA, CD4 count ≥300 cells/µl, and HIVRNA <10,000 copies/ml were included. Patients were given peg-IFN 80-150 µg/week plus ribavirin 800-1200 mg/day. Treatment was scheduled for 24 weeks for genotypes 2/3 and 48 weeks for genotypes 1/4. In an intent- to-treat analysis, 16 (26.7%) patients achieved a sustained virological response (SVR). Twenty patients (33.3%) discontinued treatment prematurely, but only in 10 (16.6%) was discontinuation due to adverse events. Negative predictive values for SVR on the basis of HCV-RNA decline between baseline and week 4 were 100% for 1- and 2-log10 fall, and positive predictive values were 40% and 58.3% for 1- and 2-log10 fall, respectively. CD4 fell by a median of 216 cells during treatment, but no HIV-associated complications occurred. In conclusion, treatment with peg-IFN alfa-2b plus ribavirin is safe and clears RNA-HCV in about one-quarter of HIV-infected patients with CHC. Efforts should be focused on optimizing management of side effects and counseling to improve adherence and to keep patients on treatment. Assessment of HCV-RNA at week 4 may help guide early therapeutic decision making. | - |
dc.format.extent | 6 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Mary Ann Liebert | - |
dc.relation.isformatof | Reproducció del document publicat a: http://online.liebertpub.com/doi/abs/10.1089/aid.2006.22.315 | - |
dc.relation.ispartof | Aids Research and Human Retroviruses, 2006, vol. 22, num. 4, p. 315-320 | - |
dc.rights | (c) Mary Ann Liebert, 2006 | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Interferó | - |
dc.subject.classification | Efecte dels medicaments sobre els microorganismes | - |
dc.subject.classification | Medicaments antivírics | - |
dc.subject.classification | Infeccions per VIH | - |
dc.subject.classification | Hepatitis C | - |
dc.subject.other | Interferon | - |
dc.subject.other | Effect of drugs on microorganisms | - |
dc.subject.other | Antiviral agents | - |
dc.subject.other | HIV infections | - |
dc.subject.other | Hepatitis C | - |
dc.title | Efficacy and safety of Pegylated Interferon-α2b Plus Ribavirin for the treatment of chronic hepatitis C in HIV-infected patients | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 544486 | - |
dc.date.updated | 2018-01-10T11:29:09Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 16623633 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
544486.pdf | 81.16 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.